Trials / Completed
CompletedNCT05328297
A Study of JNJ-55308942 in the Treatment of Bipolar Depression
A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-55308942 | JNJ-55308942 capsules will be administered orally. |
| DRUG | Placebo | Matching placebo capsules will be administered orally. |
Timeline
- Start date
- 2022-06-03
- Primary completion
- 2024-05-17
- Completion
- 2024-05-17
- First posted
- 2022-04-14
- Last updated
- 2025-07-11
- Results posted
- 2025-07-11
Locations
44 sites across 4 countries: United States, Canada, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05328297. Inclusion in this directory is not an endorsement.